Dr Lalchandani Labs Limited IPO Message Board (Page 1)

whhhha today Up 7.5%

DON'T SELL IT IT WILL BE MULTIBAGAR LIKE Dr. Lal PathLabs Ltd IN NEXT 10 YEAR SO DON'T SOLD IT IF YOU HAVE EXTRA MONEY IF YOU DON'T HAVE SOLD IT

Any suggestion on Dr. LAL LAB SHALL I HOLD IT AND AVERAGE IT OR SELL and BOOK LOSS

sell .
fair value is 12 rs

Manipulated Financials. CLEAR AVOID!

Never invest any ipo where lead manager will Navigant Corporate Advisors Ltd Lead Manager last 3 IPOs are trading in huge discount totly failed leadmanager.

Carn Mohan I already told u before.however u can use the money to invest in dhruv to get profits and cover ur losses from this one. Next in line from navigant is sirca paints. I hope people learn lesson and not subscribe sirca at all

Navigant Corporate Advisors Ltd is not a good lead manager Loot liya

Lal Lal Chand pr Nya Nya Loss dekhkr bhayo ka mood bigd gya

Sold all shares ,Lead manager very poor.

chore hai sala

Listed below issue price at 29.95. as predicted. Congratulation to navigant for 3 continuous listing Badly. Continental seeds then power instrumentation and this one. Next in line Is sirca paints

Dhruv is Hem

Laskya is funny. He doesn't know company fundamentals and hasn't studied or gone through prospectus of dhruv and is either eager to buy at good price. Dhruv will be a multibagger in long run. Lol. Keep dreaming as no-one is interested in your comments

Lower circuit 28.5

Listing should be around 31
Let's see. Good luck!!

Listing today.

Best wishes to allottees.

Very good company easily cross Rs 60/

Its a sell on listing day stock.
Navigant has reputation and very bad movement of all its scrip and mostly on downside

Anybody received allotted shares in D.mat account

Got msg but yet not credited in D-mat account

10

What is the listing date?

2 Applied and 1 allotted

If we annualize latest earnings and attribute it on fully diluted equity post issue, then asking price is at a P/E of around 10 thus issue appears reasonably priced. As per offer document it has no listed peers. Although on the basis of scale, they are not comparable in true sense, we may consider main board peers like Thyrocare, Dr. Lal Path that are trading at a P/E of around 38 and 43 (as on 18.04.18 closing).